Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Maria Isabel Fernandes Lopes, Letícia Pastorelli Bonjorno, Marcela C Giannini, et al.
RMD Open (2021) Vol. 7, Iss. 1, pp. e001455-e001455
Open Access | Times Cited: 229

Showing 1-25 of 229 citing articles:

Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Inflammasome activation at the crux of severe COVID-19
Setu M. Vora, Judy Lieberman, Hao Wu
Nature reviews. Immunology (2021) Vol. 21, Iss. 11, pp. 694-703
Open Access | Times Cited: 288
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Jean‐Claude Tardif, Nadia Bouabdallaoui, Philippe L. L’Allier, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 8, pp. 924-932
Open Access | Times Cited: 258
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1419-1426
Open Access | Times Cited: 171
Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*
Eleni Karakike, Evangelos J. Giamarellos‐Bourboulis, Miltiades Kyprianou, et al.
Critical Care Medicine (2021) Vol. 49, Iss. 12, pp. 2042-2057
Open Access | Times Cited: 140
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Reyes, Kelly A Hu, Jacob Teperman, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 5, pp. 550-557
Open Access | Times Cited: 139
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
Nicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, et al.
EBioMedicine (2022) Vol. 85, pp. 104299-104299
Open Access | Times Cited: 78
Persistent Oxidative Stress and Inflammasome Activation in CD14highCD16− Monocytes From COVID-19 Patients
Silvia Lucena Lage, Eduardo P. Amaral, Kerry L. Hilligan, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 77
Innate immunity, cytokine storm, and inflammatory cell death in COVID-19
Rajendra Karki, Thirumala‐Devi Kanneganti
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 72
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Neutrophils in COVID-19: recent insights and advances
Jiayu Li, Kegong Zhang, Ye Zhang, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 42
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action
Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, et al.
Biochemical Pharmacology (2020) Vol. 183, pp. 114296-114296
Open Access | Times Cited: 100
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Timotius Ivan Hariyanto, Devina Adella Halim, Claudia Jodhinata, et al.
Clinical and Experimental Pharmacology and Physiology (2021) Vol. 48, Iss. 6, pp. 823-830
Open Access | Times Cited: 74
Pericarditis in patients with COVID-19: a systematic review
Carlos Diaz‐Arocutipa, Jose Saucedo‐Chinchay, Massimo Imazio
Journal of Cardiovascular Medicine (2021) Vol. 22, Iss. 9, pp. 693-700
Open Access | Times Cited: 63
Potential Antiviral Action of Alkaloids
Frage Abookleesh, Bader Al-Anzi, Aman Ullah
Molecules (2022) Vol. 27, Iss. 3, pp. 903-903
Open Access | Times Cited: 63
Colchicine for the treatment of COVID-19
Agata Mikołajewska, Anna-Lena Fischer, Vanessa Piechotta, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 58
Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks
Hossam H. Tayeb, Raed I. Felimban, Sarah Almaghrabi, et al.
Colloids and Interface Science Communications (2021) Vol. 45, pp. 100533-100533
Open Access | Times Cited: 58
Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology
Camila M. Silva, Carlos W. Wanderley, Flávio P. Veras, et al.
Critical Care (2022) Vol. 26, Iss. 1
Open Access | Times Cited: 57
The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications
Douglas B. Kell, Etheresia Pretorius
Biochemical Journal (2022) Vol. 479, Iss. 16, pp. 1653-1708
Open Access | Times Cited: 52
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Xue Li, Ziqi Zhang, Zhenling Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Aldo Bonaventura, Alessandra Vecchiè, Lorenzo Dagna, et al.
Inflammation Research (2022) Vol. 71, Iss. 3, pp. 293-307
Open Access | Times Cited: 42
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis
Nicola Potere, Evan C. Garrad, Yogendra Kanthi, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 11, pp. 2046-2060
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top